VERA - Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25 2024 | Benzinga
BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced it will host an in-person R&D day featuring Richard Lafayette, M.D., FACP, from Stanford University Medical Center, who will join company management to present Phase 2b eGFR and proteinuria data from week 72 of the ORIGIN Phase 2b clinical trial of atacicept for the treatment of IgA nephropathy (IgAN), and Jonathan Barratt, Ph.D., FRCP, from the University of Leicester for a discussion of the results, on January 25, 2024. To register, click here.
| Presentation Details: |
| Date: |
| Thursday, January 25, 2024 |
| Time: |
| 8:00 AM ET |
| Location: |
| Lotte New York Palace Hotel, 455 Madison Ave, New York, NY 10022 United States |
| Webcast: |
| https://lifescievents.com/event/veratx/ |
About Richard Lafayette, M.D., FACP
Dr. Lafayette is a Professor of Medicine (Nephrology) and Director of the Stanford Glomerular Disease Center at Stanford University Medical Center. Dr. Lafayette completed his medical education at New York Medical College and went on to complete his residency at the Long Island Jewish Medical Center, and his fellowship at Stanford University School of Medicine. Dr. Lafayette is board-certified in Internal Medicine and Nephrology. Dr. Lafayette served as the Associate Chair of the Stanford University Department of Medicine from 2002 to 2007, the Clinical Chief of Nephrology at Stanford University from 1999 to 2012, and currently serves as the Director of the Stanford Glomerular Disease Center since 2010. Dr. Lafayette was honored in America's Top Doctors, Best Doctors from 2004 to 2018, and received America's Top Doctors Award, Castle Connolly Medical Ltd. from 2014 to 2022. Dr. Lafayette has been part of the following boards and professional organizations: Editorial Board, Kidney News, American Society of Nephrology (2010 – 2021) Member, Glomerular Disease Advisory Committee, American Society of Nephrology (2013 – 2017) Member (ex-officio), Communications Committee, American Society of Nephrology (2015 – Present).
About Jonathan Barratt Ph.D., FRCP
Dr. Barratt leads the Renal Research Group within the College of Life Sciences, University of Leicester. His research is focused on a bench-to-bedside approach to improving our understanding of the pathogenesis of IgAN, a common global cause of kidney failure. Dr. Barratt is the IgAN Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR), and a member of the steering committee for the International IgAN Network. He works closely with pharmaceutical companies interested in new treatments for IgAN, is ...